top of page
A Vision Without Eye Disease
PulseMedica is developing a platform that is intended to be the first safe, effective, and non-invasive system to screen and treat vitreoretinal disease, starting with symptomatic vitreous opacities (eye floaters).
_edited.png)
Backed by Leading Investors
Millions Worldwide Suffering from Eye Disease
Conditions such as vitreous floaters, age-related macular degeneration (AMD), diabetic retinopathy, and vitreomacular traction affect hundreds of millions of people worldwide.
The Impact of Eye Floaters
52% of adults have floaters, where 5-10% of those impacted experience severe impairments and have no safe and non-invasive treatment options.
-
Vision Impairments
-
Anxiety
-
Stress
-
Depression
-
Reduced Quality of Life
Severe Floaters
Moderate Floaters
Vision Without Floaters
Severe Floaters
1/4
Mild, moderate, and severe impairments from floaters.
The Need For Floater Treatment
There is a significant unmet need for a safe, effective and non-invasive office-based device to screen, diagnose, and treat eye floaters.
Platform Technology
High-Resolution Real Time Imaging
Enhanced Laser Accuracy & Safety
Automated Treatment & Planning
Image Guided Laser Treatment
PulseMedica News and Updates
Latest developments, investments, and breakthroughs in our journey
bottom of page